Please enable JavaScript to continue using this application.

Compare $GLUE vs $OBX | Chartloom

Compare

$GLUE vs $OBX

Monte Rosa Therapeutics Inc · Obsidian Therapeutics, Inc

GLUE

Monte Rosa Therapeutics Inc

OBX

Obsidian Therapeutics, Inc

Compare $GLUE vs $OBX

Comparing Monte Rosa Therapeutics Inc and Obsidian Therapeutics, Inc

GLUEMonte Rosa Therapeutics Inc

OBXObsidian Therapeutics, Inc

GLUEMonte Rosa Therapeutics Inc

Market cap

$870M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

21.85x

Rev growth (TTM)

-83.9%

YTD performance

-32.7%

52W performance

33.6%

FCF yield

-3.7%

OBXObsidian Therapeutics, Inc

Market cap

$803M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-61.8%

52W performance

-61.8%

FCF yield

0.0%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

GLUE

OBX

Detailed metrics comparison

GLUE

Monte Rosa Therapeutics Inc

OBX

Obsidian Therapeutics, Inc

Market Cap

GLUE$870M

OBX$803M

Enterprise Value

GLUE$780M

OBX$803M

Price

GLUE$10.30

OBX$13.00

P/E Ratio

GLUEN/A

OBXN/A

P/S Ratio

GLUE30.29x

OBX0.00x

EV/Sales

GLUE27.15x

OBX0.00x

EV/EBITDA

GLUE47.84x

OBX0.00x

P/B Ratio

GLUE1.84x

OBXN/A

P/FCF Ratio

GLUEN/A

OBXN/A

EV/FCF

GLUE-24.32x

OBX0.00x

PEG Ratio

GLUEN/A

OBXN/A

Forward P/E (NTM)

GLUEN/A

OBXN/A

Forward P/S (NTM)

GLUE21.85x

OBXN/A

Revenue (TTM)

GLUE$29M

OBX$0

Revenue Growth (YoY)

GLUE-83.9%

OBXN/A

Forward Rev Growth

GLUE-58.1%

OBX0.0%

Gross Margin (TTM)

GLUE0.0%

OBX0.0%

Operating Margin (TTM)

GLUE0.0%

OBX0.0%

EBITDA Margin (TTM)

GLUE-604.8%

OBX0.0%

Net Margin (TTM)

GLUE-560.9%

OBX0.0%

FCF Margin (TTM)

GLUE-111.7%

OBXN/A

Net Income (TTM)

GLUE$-161M

OBXN/A

FCF (TTM)

GLUE$-32M

OBX$0

EPS (TTM)

GLUE-$1.59

OBX$0.00

ROE (TTM)

GLUE-4331.0%

OBX0.0%

ROA (TTM)

GLUE-2759.0%

OBX0.0%

ROIC (TTM)

GLUE-4331.0%

OBX0.0%

Cash

GLUE$90M

OBX$0

Debt

GLUE$0

OBX$0

Net Cash/Debt

GLUE$90M

OBX$0

Current Ratio (TTM)

GLUE10.58x

OBX0.00x

Quick Ratio (TTM)

GLUE10.49x

OBX0.00x

Debt/Equity (TTM)

GLUE0.00x

OBX0.00x

Debt/Assets (TTM)

GLUE0.0%

OBX0.0%

Interest Coverage (TTM)

GLUEN/A

OBXN/A

Net Debt/EBITDA (TTM)

GLUE0.00x

OBX0.00x

Beta

GLUE1.34

OBX5.86

52W Performance

GLUE33.6%

OBX-61.8%

YTD Performance

GLUE-32.7%

OBX-61.8%

% from 52W High

GLUE-60.0%

OBX-74.0%

% from 52W Low

GLUE34.7%

OBX7.7%

Asset Turnover (TTM)

GLUE0.05x

OBX0.00x

FCF Yield (TTM)

GLUE-3.7%

OBX0.0%

Earnings Yield (TTM)

GLUE-18.5%

OBX0.0%

Dividend Yield (TTM)

GLUEN/A

OBXN/A

Rule of 40

GLUE-195.5

OBX0.0

EV/GP/RG

GLUEN/A

OBXN/A

Ticker research

View GLUE research View OBX research

Metric	GLUE Monte Rosa Therapeutics Inc	OBX Obsidian Therapeutics, Inc
Market & Valuation
Market Cap	$870M	$803M
Enterprise Value	$780M	$803M
Price	$10.30	$13.00
P/E Ratio	N/A	N/A
P/S Ratio	30.29x	0.00x
EV/Sales	27.15x	0.00x
EV/EBITDA	47.84x	0.00x
P/B Ratio	1.84x	N/A
P/FCF Ratio	N/A	N/A
EV/FCF	-24.32x	0.00x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	21.85x	N/A
Revenue & Growth
Revenue (TTM)	$29M	$0
Revenue Growth (YoY)	-83.9%	N/A
Forward Rev Growth	-58.1%	0.0%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-604.8%	0.0%
Net Margin (TTM)	-560.9%	0.0%
FCF Margin (TTM)	-111.7%	N/A
Net Income (TTM)	$-161M	N/A
FCF (TTM)	$-32M	$0
EPS (TTM)	-$1.59	$0.00
ROE (TTM)	-4331.0%	0.0%
ROA (TTM)	-2759.0%	0.0%
ROIC (TTM)	-4331.0%	0.0%
Financial Health
Cash	$90M	$0
Debt	$0	$0
Net Cash/Debt	$90M	$0
Current Ratio (TTM)	10.58x	0.00x
Quick Ratio (TTM)	10.49x	0.00x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.34	5.86
52W Performance	33.6%	-61.8%
YTD Performance	-32.7%	-61.8%
% from 52W High	-60.0%	-74.0%
% from 52W Low	34.7%	7.7%
Efficiency & Yields
Asset Turnover (TTM)	0.05x	0.00x
FCF Yield (TTM)	-3.7%	0.0%
Earnings Yield (TTM)	-18.5%	0.0%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-195.5	0.0
EV/GP/RG	N/A	N/A
Ticker research	View GLUE research	View OBX research

Valuation

P/S Ratio

OBX

0.00x

GLUE

30.29x

EV/FCF

GLUE

-24.32x

OBX

0.00x

Growth & revenue

Revenue Growth TTM

GLUE

-83.9%

Forward Revenue Growth

OBX

0.0%

GLUE

-58.1%

Profitability & performance

Gross Margin

GLUE

0.0%

OBX

0.0%

ROE

OBX

0.0%

GLUE

-4331.0%

FCF Yield %

OBX

0.0%

GLUE

-3.7%

52-Week Performance

GLUE

33.6%

OBX

-61.8%

Detailed metrics comparison

GLUE

Monte Rosa Therapeutics Inc

OBX

Obsidian Therapeutics, Inc

Market Cap

GLUE$870M

OBX$803M

Enterprise Value

GLUE$780M

OBX$803M

Price

GLUE$10.30

OBX$13.00

P/E Ratio

GLUEN/A

OBXN/A

P/S Ratio

GLUE30.29x

OBX0.00x

EV/Sales

GLUE27.15x

OBX0.00x

EV/EBITDA

GLUE47.84x

OBX0.00x

P/B Ratio

GLUE1.84x

OBXN/A

P/FCF Ratio

GLUEN/A

OBXN/A

EV/FCF

GLUE-24.32x

OBX0.00x

PEG Ratio

GLUEN/A

OBXN/A

Forward P/E (NTM)

GLUEN/A

OBXN/A

Forward P/S (NTM)

GLUE21.85x

OBXN/A

Revenue (TTM)

GLUE$29M

OBX$0

Revenue Growth (YoY)

GLUE-83.9%

OBXN/A

Forward Rev Growth

GLUE-58.1%

OBX0.0%

Gross Margin (TTM)

GLUE0.0%

OBX0.0%

Operating Margin (TTM)

GLUE0.0%

OBX0.0%

EBITDA Margin (TTM)

GLUE-604.8%

OBX0.0%

Net Margin (TTM)

GLUE-560.9%

OBX0.0%

FCF Margin (TTM)

GLUE-111.7%

OBXN/A

Net Income (TTM)

GLUE$-161M

OBXN/A

FCF (TTM)

GLUE$-32M

OBX$0

EPS (TTM)

GLUE-$1.59

OBX$0.00

ROE (TTM)

GLUE-4331.0%

OBX0.0%

ROA (TTM)

GLUE-2759.0%

OBX0.0%

ROIC (TTM)

GLUE-4331.0%

OBX0.0%

Cash

GLUE$90M

OBX$0

Debt

GLUE$0

OBX$0

Net Cash/Debt

GLUE$90M

OBX$0

Current Ratio (TTM)

GLUE10.58x

OBX0.00x

Quick Ratio (TTM)

GLUE10.49x

OBX0.00x

Debt/Equity (TTM)

GLUE0.00x

OBX0.00x

Debt/Assets (TTM)

GLUE0.0%

OBX0.0%

Interest Coverage (TTM)

GLUEN/A

OBXN/A

Net Debt/EBITDA (TTM)

GLUE0.00x

OBX0.00x

Beta

GLUE1.34

OBX5.86

52W Performance

GLUE33.6%

OBX-61.8%

YTD Performance

GLUE-32.7%

OBX-61.8%

% from 52W High

GLUE-60.0%

OBX-74.0%

% from 52W Low

GLUE34.7%

OBX7.7%

Asset Turnover (TTM)

GLUE0.05x

OBX0.00x

FCF Yield (TTM)

GLUE-3.7%

OBX0.0%

Earnings Yield (TTM)

GLUE-18.5%

OBX0.0%

Dividend Yield (TTM)

GLUEN/A

OBXN/A

Rule of 40

GLUE-195.5

OBX0.0

EV/GP/RG

GLUEN/A

OBXN/A

Ticker research

View GLUE research View OBX research

Metric	GLUE Monte Rosa Therapeutics Inc	OBX Obsidian Therapeutics, Inc
Market & Valuation
Market Cap	$870M	$803M
Enterprise Value	$780M	$803M
Price	$10.30	$13.00
P/E Ratio	N/A	N/A
P/S Ratio	30.29x	0.00x
EV/Sales	27.15x	0.00x
EV/EBITDA	47.84x	0.00x
P/B Ratio	1.84x	N/A
P/FCF Ratio	N/A	N/A
EV/FCF	-24.32x	0.00x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	21.85x	N/A
Revenue & Growth
Revenue (TTM)	$29M	$0
Revenue Growth (YoY)	-83.9%	N/A
Forward Rev Growth	-58.1%	0.0%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-604.8%	0.0%
Net Margin (TTM)	-560.9%	0.0%
FCF Margin (TTM)	-111.7%	N/A
Net Income (TTM)	$-161M	N/A
FCF (TTM)	$-32M	$0
EPS (TTM)	-$1.59	$0.00
ROE (TTM)	-4331.0%	0.0%
ROA (TTM)	-2759.0%	0.0%
ROIC (TTM)	-4331.0%	0.0%
Financial Health
Cash	$90M	$0
Debt	$0	$0
Net Cash/Debt	$90M	$0
Current Ratio (TTM)	10.58x	0.00x
Quick Ratio (TTM)	10.49x	0.00x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.34	5.86
52W Performance	33.6%	-61.8%
YTD Performance	-32.7%	-61.8%
% from 52W High	-60.0%	-74.0%
% from 52W Low	34.7%	7.7%
Efficiency & Yields
Asset Turnover (TTM)	0.05x	0.00x
FCF Yield (TTM)	-3.7%	0.0%
Earnings Yield (TTM)	-18.5%	0.0%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-195.5	0.0
EV/GP/RG	N/A	N/A
Ticker research	View GLUE research	View OBX research